Panacea Biotec is excited to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose live-attenuated tetravalent vaccine.

According to the World Health Organization, Dengue represents one of the ten biggest global health threats, and it is critical that we have access to a safe and effective vaccine candidate that can reduce the devastating impact of Dengue fever in endemic regions.

Speaking on the occasion, Dr Rajesh Jain, Managing Director, said “DengiAll’s Phase I/II study results are even more important in the context of the Covid-19 pandemic. Co-infection of Dengue and Covid-19 in a Dengue endemic India may complicate approach to treatment and strain healthcare infrastructure. Panacea Biotec has already approached the DGCI to seek accelerated review of its data to bring DengiAll to market quickly and reduce the burden on our healthcare infrastructure.”

Dr Lalitendu Mohanty, Head of Clinical Research, said, “Dengue fever’s unique characteristics make vaccine development tricky and an ideal Dengue vaccine must be safe and offer balanced and robust immune response against all four Dengue serotypes. This is where we believe that DengiAll has shown promising results. I would like to thank virologist Dr Steven Whitehead and the team at the National Institute of Allergy and Infectious Disease, the US and infectious disease specialist Dr Anna Durbin at the John Hopkins School of Public Health for their continued and unfettered support in this journey to bring DengiAll to market.”

Mr Devender Gupta, Chief Financial Officer, said, “We would like to thank Technology Development Board, Ministry of Science and Technology for supporting Panacea Biotec through financial and technical resources to make DengiAll’s Phase I/II a success.”

DengiAll has illustrated the strength of Panacea Biotec’s expertise in vaccinology, research, development, and manufacturing while leveraging NIH’s ability to work on complex biological challenges to develop breakthrough technologies. Panacea Biotec through the continued support from National Institutes of Health, Technology Development Board, and other stakeholders is in a better position to increase affordable access to DengiAll to fight Dengue, a disease that has eluded mankind for generations. With more than 3.9 billion people living in Dengue endemic areas and over 390 million infections per year, DengiAll targets a global market of over $3 billion.

Vaccines prevent 2 to 3 million deaths each year and have transformed global public health. For the past 30 years, Panacea Biotec has supplied vaccines to protect the health of people across the world; it has a strong track record of supplying more than 10 billion doses of Polio vaccines and over 150 million doses of Innovative fully-liquid Vaccines to National Governments, UN Agencies, etc. Panacea Biotec’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as Dengue. The team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world’s most pressing public health needs.